Shilpa Biologicals, a wholly owned subsidiary of Shilpa Medicare, has appointed Dr. Sridevi Khambhampaty as Chief Executive Officer (CEO) w.e.f. 19th September, 2024. 

Dr. Sridevi Khambhampaty is a recognized leader in the Biologics industry with over two decades of expertise in developing products for the Indian, US and EU markets. In addition to her strong technical competence, she is regarded as an exceptional people leader who has consistently built high performing teams. Her deep understanding of the regulatory and compliance requirements of biologics development and manufacturing coupled with her business acumen make her highly suited for leading Shilpa Biologics into an extraordinary growth phase.

Sridevi has a PhD in Biophysics from NCBS-TIFR Bangalore, and also has a postdoctoral fellowship from Stanford University, California.

She brings an overall Techno Commercial experience of 22+ Years in various Organizations, notably in Lymphoma and Leukemia Research Foundation, Dr. Reddy’s, Intas Pharmaceuticals and here most recent assignment was with Syngene International Ltd.